Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have been given an average recommendation of “Moderate Buy” by the eleven analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $42.4286.

Several equities analysts have recently commented on DMRA shares. Wedbush restated an “outperform” rating and issued a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, June 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 18th. Royal Bank Of Canada began coverage on Damora Therapeutics, Inc. Common Stock in a research note on Friday, April 24th. They set an “outperform” rating and a $40.00 price target on the stock. HC Wainwright started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They set a “buy” rating and a $45.00 price target for the company. Finally, Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They issued an “outperform” rating and a $46.00 price objective for the company.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Hedge funds have recently made changes to their positions in the business. Ikarian Capital LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter valued at approximately $6,574,000. Jain Global LLC acquired a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $2,774,000. Remedium Capital Partners LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,772,000. Boothbay Fund Management LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at approximately $2,204,000. Finally, Connective Capital Management LLC acquired a new position in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth $100,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA traded up $0.46 during trading hours on Tuesday, hitting $30.26. 138,343 shares of the company’s stock traded hands, compared to its average volume of 372,567. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The company has a market capitalization of $1.86 billion, a PE ratio of -5.42 and a beta of 1.46. The firm’s 50-day moving average is $23.96 and its 200-day moving average is $25.43.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its earnings results on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Equities research analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 earnings per share for the current fiscal year.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.